title: Effect of oxybuprocaine eye drops on corneal volume and thickness measurements.
abstract: OBJECTIVE
  To investigate the effect of oxybuprocaine eye drops on corneal volume (CV) and corneal thickness measurements.
  
  
  METHODS
  Central corneal thickness (CCT), corneal thinnest point (CTP), and CV of 78 eyes of 78 healthy volunteers were measured with Pentacam, before and 5 min after the administration of oxybuprocaine eye drops. The fellow non-anesthetized eyes were used as control.
  
  
  RESULTS
  Before topical anesthesia, the mean CCT was 546.76 ± 35.3 μm, after anesthesia, it was 547.76 ± 36.56 μm (p = 0.86). In the fellow eyes, the first mean CCT was 548.82 ± 35.2 μm and the second was 547.55 ± 35.9 μm (p = 0.82). The mean CTP before anesthesia was 543.99 ± 35.23 μm, after it was 544.89 ± 36.3 μm (p = 0.88). In the fellow eyes, the first mean CTP was 544.15 ± 35.35 μm and the second was 542.81 ± 36 μm (p = 0.81). Before topical anesthesia, the mean CV was 60.55 ± 3.84 mm, after it was 60.66 ± 3.97 mm (p = 0.86). In the fellow eyes, the first mean CV was 60.93 ± 3.87 mm and the second was 60.73 ± 4 mm (p = 0.75).
  
  
  CONCLUSIONS
  Oxybuprocaine eye drops do not appear to induce a significant corneal swelling and do not affect the measurements when comparing CCT measured with optical or ultrasound devices.
authors.affiliation: Eye Department, Second University of Naples, Naples, Italy. nicola.rosa@unina2.it
authors.forename: Nicola
authors.initials: N
authors.lastname: Rosa
authors.forename: Maddalena
authors.initials: M
authors.lastname: De Bernardo
authors.forename: Maria
authors.initials: M
authors.lastname: Borrelli
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Filosa
authors.forename: Michele
authors.initials: M
authors.lastname: Lanza
mesh_terms: D000328:Adult; D000779:Anesthetics, Local / Q000008:administration & dosage*; D003315:Cornea / Q000033:anatomy & histology* / Q000187:drug effects*; D003941:Diagnostic Techniques, Ophthalmological / Q000295:instrumentation*; D005260:Female; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D011343:Procaine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D055815:Young Adult
chemical_list: D000779:Anesthetics, Local; D009883:Ophthalmic Solutions; D011343:Procaine; C005298:benoxinate